Resurrection of antibody as a therapeutic drug

Hong Keun Chung¹, Junho Chung²

Department of Biochmietry and cancer Research Institute, Seoul National University Collage of Madicine, Department of Biochmietry, cancer Research Institute, Seoul National University Collage of Madicine and Department of Basic Science, National Cancer Center

Currently 18 monoclonal antibodies were approved by FDA for injection into humans for therapeutic or diagnostic purpose. And 146 clinical trials are under way to evaluate the efficacy of monoclonal antibodies as anti-cancer agents, which comprise 9 % of clinical trials in cancer therapy field. When considering a lot of disappointment and worries existed in this field during the past 15 years, this boom could be called as resurrection. Antibodies have several merits over small molecule drug. First of all it is easier and faster in development, as proper immunization of the target proteins usually raises good antibody response. The side effects of antibodies are more likely to be checked out in immunohistomchemical staining of whole human tissues. Antibody has better pharmacokinetics, which means a longer half-life. And it is non-toxic as it is purely a "natural drug. Vast array of methods was developed to get the recombinant antibodies to be used as drug. The mice with human immunoglobulin genes were generated. Fully human antibodies can be developed in fast and easy way from these mice through immunization. These mice could make even human monoclonal antibodies against any human antigen like albumin. The concept of combinatorial library was also actively adopted for this purpose. Specific antibodies can be screened out from phage, mRNA, ribosomal library displaying recombinant antibodies like single chain Fvs or Fabs. Then the coding genes of these specific antibodies are obtained from the selected protein-gene units, and used for industrial scale production. Both naïve and immunized libraries are proved to be effective for this purpose. In post-map arena, antibodies are receiving another spotlight as molecular probes against numerous targets screened out from functional genomics or proteomics. Actually many of these antibodies used for this purpose are already human ones. Through alliance of these two actively growing research areas, antibody would play a central role in target discovery and drug development.

Key Words: antibody, drug

: .

E-mail: hkchung @snu.ac.kr

110-799, 28 Tel: 02)740-8243, Fax: 02)744-4534

2000 1450 (1),

2000

molecule

	가 가 .			
2000 7 24 Fo	orbe , Merck (38),	(Biotechnology),		
Procter & Gamble (47), Nestle (49), Pfizer (50),			
Johnson & Johnson (56), El du Pont de Nemours (58			
), Roche Group (7	(9), Novartis Group (85),	가	, small	
Bristol-Myer Squibb (98	9	molecule drug	가	
가 100	, 1999	, 가		
2,550			small molecule drug	
Pfizer Via	gra			
4		(biological drug)		
가	OECD		가	
가	10%	Amgen	, 가	
,	가 1996 ~	38	Merck 1/3	
2000 5	2 가	,	Merck 1/10	
(2), 가		1 M	erck 가 ,	
		Merck 40%	•	
Post-Map			small	
		molecule drug		
2001 2 16	science Celera 가,		가	
The International Human Genome			500	
Sequencing Consortium (IHGSC) Nature			80	
	(3).	(4).		
	가		,	
		가		
. 2001 1	Millennium Pharmaceutical inc.			
(MLNM) Bayer AG	가	:		
Phase I				
genome drug candidate	database Zeus	-1		
	8 product testing	가	. 1990	
	product testing 2 8	(recombinant antibody		
2		•	FDA 가	
5,000 ~ 10,000	5	_	12 ,	
	,	6	(Table I). 1998	
	500		tech, Amgen, Chiron, Centocor,	
			za, Genetics Institute, Gensia	
(2)	MINIM	Pharm, Immunex	biotechnology	
(3).	MLNM gene	50 (450)	168	
analysis software	3,000 ~ 5,000	78 (46%)		
druggable protein	, Zeus	2001 4 17	Genentech	
	mRNA expression level	2001 4 17 prod	luct pipeline 20	
,	sm all		, 9 가	

8 .

 $CancerNet \quad \ (http://$

Table I. The list of FDA-approved antibody drug

Antibody	Antigen	Indication
Therapeutic use		
OKT3	CD3	Acute kidney transplantation
Digibind	Digoxin	Digoxin poisoning
Herceptin	HER- 2	Metastatic.breast cancer
Panorex	CA 17-1A	Colorectal cancer
Remicade	TNFa	Crohn's disease
Reopro	Platelet	Ischemic cardiac complication
Syangis	RSV	RSV infection
Zenapax	IL2 R-a	Kindney transplantation rejec
Basiliximab	IL2 R-a	Acute organ rejection
Rituxan	CD20	Non-Hodgkin's lymphoma
Mylotarg	CD33	Relapsed CD33-positive AML
Campath	CD 52	B-cell CLL

In vivo diagnostic use

CEA Scan

LeukoScan

OncoScint CR/OV

ProstaScint

RIGSCAN CR49

Verluma

```
cancernet.nci.nih.gov/trialsrch.shtml)
                                       2001
                                                    17
                                                                                   (side effect)
                                                                              가
                                                                                                          가
                        1,647
                                                                                   (additional group)
                  clinical trial
                                       146
9%
                             5~6
                     20\,10
                               5
                                                    20
                                                              가
                                                      가
                                                                                     가
                         (5).
                                                                 가
                                                                                 가
                                                      가
         가 가
                                                                                    (natural drug)
                                                                                 가
             (humanization)
                                                                                                     (half life)
```

(small molecule drug)

가 가 (non-self) HAMA(human anti-mouse immunoglobulin antibody) hypersensitivity shock (immunogenicity) heavy chain constant region light chain constant region (chimeric antibody)가 (Fig. 1). variable region framework (humanized antibody) CDR-(CDR-grafted antibody) (Fig. 1). Biovation Limited

. de-immunization

variable region

 $Reo Pro \quad Fab \qquad \qquad .$ heavy chain variable region light chain variable region (Gly 4 Ser 1) 5 linker scFv (single chain variable fragment) (Fig. 2). scFv 7 † 1/6

unit . , 가

(recombinant immunotoxin) (Fig. 2).




Fig. 1 The structure of chimeric and humanized antibody

gamma camera scanning , radioimmunoscintigraphy . radioactive compound tagging , radioimmunotherpay . Mylotarg

가 . 가 가 , plasma cell

, CHO overexpression
. B lymphocyte
(SLAM, selected lymphocyte antibody method technology) (6-9). 2000 5
22 7 XenoMouse

Abgenix Abott 가

. Medarex KIRIN

X-ray cryatal ,




Fig. 2 The structure of scFv and recombinant immunotoxin

template	PCR			가 (13)).
		,			. 7
		가		sequence 가	frameworl
		trial-and-error	region		, CDR grafting
	(affinity)			CDR grafting	g CDR
			framework		(14)
(10-11).			grafting		library
				panning	
	•			•	
Combinatorial phage	e display libra	ry	Display vehicle	e phage	
	, 가	,			. mRNA
(spleen),	(bone m	narrow)	protein fusion	(15).	mRNA puro
PCR		, phage display	mycin	linker	, in-vitro
vector pha	age coat	display	translation	mRNA가 translat	ion C
phage	panning		terminal		mRNA
•		variable region	protein con	mplex	
	,	가	protein interaction	n	
framework region	가		com	plex	PCR
, CDR grafting	가				in-vitro trans
diversify antibod	y library	,	cription in-vit	ro translation	complexフ
panning 가	가			selection cycle	
(12).		가			
,		,	. mRNA-protein fusion system		
			library construction	on	, library size가
co	omplex antiger	ı, (plasma	,	molecular inter	raction
membrane)				. Messenger	RNA가 ribosome
biological fluid			translat	ion , ribosome	release
				mRNA rib	osome
		. 가	riboso	omal display	
	가 (v	variable region) 가	(10	6).	
(constant region)			Cambridge Antibody Technology (CAT)		
chimeric Fab phage display combinatorial			biotech		premade antibody
rabbit/human chimeric Fab phage display library			library		
		library			,
р	anning	chime-	1 × 10 ¹¹	diversity 가	naive library
ric .		가		(kd < 1 x	10 ⁻⁷)
가 .	가		panning		(17).
immunoglob		arrangement mecha-	synthetic CDF	R human ant	ibody phage display
nism 가	-	gene	library		panning
conversion mechanism	가	11	-		(18).

가

E. coli prokaryote , yeast, CHO , transgenic animal, plant . 가 가

tobacco, corn plant plantibody

catalytic antibody

가 가

. catalytic antibody7

. catalytic

antibody prodrug 71

antigen binding pocket pocket

pocket

catalytic function 71 design prodrug prodrug

drug . 가

가 가

- 1. Playing with pain killers Newsweek April 9, 145-159, 2000
- 2. 500 hundreds International Corporation Forbes July 24th. 2000
- 3. Genomania meets the bottom line, Science 291; 1193-1203, 2001

- 4. Convergence, The Biotechnology industry reports, 2001 Business Week, March 6th, 2000
- 5. Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, Humphries S, Ayling C, Goyenechea B, Xian J, Taussig MJ, Neuberger MS, Bruggemann M Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol 163; 6898-906, 1999
- 6. Tomizuka K, Shinohara T, Yoshida H, Uejima H, Ohguma A, Tanaka S, Sato K, Oshimura M, Ishida I Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 97; 722-727, 2000
- Russell ND, Corvalan JR, Gallo ML, Davis CG, Pirofski La.Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect Immun 68;1820-1826, 2000
- Michael L. Gallo, Vladimir E. Ivanov, Aya Jakobovits, and C. Geoffrey Davis. The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans European Journal of Immunology 30: 534-540, 2000
- Co MS, Landolfi NF, Nagy JO, Tan JH, Vexler V, Vasquez M, Roark L, Yuan S, Hinton PR, Melrose J, Klingbeil C, Queen C, Berg EL. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology 4(3-4):253-266, 1999
- 10. He X-Y, Xu Z, Melrose J, Mullowney A, Vasquez M., Queen C, Vexler V, Klingbeil C, Co MS, and Berg EL Humanization and pharmacokinetics of a mouse monoclonal antibody with specificity for both E- and P-selectin has now been published in Journal of Immunology 160, 1029-1035, 1998
- 11. Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS, Welt S, Old LJ, Barbas CF 3rd The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 275; 13668-13676, 2000
- 12. Raaphorst FM, Raman CS, Nall BT, Teale JM Molecular mechanisms governing reading frame choice of immunoglobulin diversity genes. Immunol Today Jan;18; 37-43, 1997

- Foote J, Winter G Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224;487-499, 1992
- 14. Hammond PW, Alpin J, Rise CE, Wright MC, Kreider BL. in vitro selection and characterization of Bcl-XL binding proteins from a mix of tissue-specific mRNA display libraries. J Biol Chem 2001 Mar 30; [epub ahead of print]
- 15. Hanes J, Schaffitzel C, Knappik A, Pluckthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display Nat Biotechnol 18; 1287-1292, 2000
- Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK,
 Pope AR, Earnshaw JC, McCafferty J, Hodits RA,
 Wilton J, Johnson KS Human antibodies with sub-

- nanomolar affinities isolated from a large nonimmunized phage display library. Nat Biotechnol 14; 309-314, 1996
- 17. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A, Virnekas B Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. 296; 57-86, 2000
- 18. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A, Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 296; 57-86, 2000

13